The pathways involved in the neuroendocrine-low differentiation of SCLC tumors (Figure 1), including YAP1, NOTCH, Wnt family (WNT), and MYC, have each been implicated in tumor progression and treatment resistance across various cancers. This evidence concerns the gene YAP1 and neoplasm.